DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors

Cancer Letters

Volumn 323, Issue 2, 2012, Pages 155-160

  Yun, Un Jung ^a,b   Park, Sang Eun ^a,b   Jo, Yong Sam ^a   Kim, Jungbin ^a   Shin, Deug Y ^a,b  

^a Dankook University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

DNA damage; IL 6; Senescence; STAT3; Tumor

Indexed keywords

DNA; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE 1; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL AGING; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; DNA DAMAGE; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BASE SEQUENCE; CELL AGING; CELL DIVISION; CELL LINE, TUMOR; DNA DAMAGE; DNA PRIMERS; GENE SILENCING; HUMANS; INTERLEUKIN-6; NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 84863104297     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.003     Document Type: Article

References (30)

1. Bakkenist C.J., Kastan M.B. Initiating cellular stress responses. Cell 2004, 118:9-17.
2. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat. Rev. Cancer 2008, 8:512-522.
3. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., Aarden L.A., Mooi W.J., Peeper D.S. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
4. Rodier F., Coppe J.P., Patil C.K., Hoeijmakers W.A., Munoz D.P., Raza S.R., Freund A., Campeau E., Davalos A.R., Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11:973-979.
5. Campisi J., d'Adda di Fagagna F. Cellular senescence. when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 2007, 8:729-740.
6. Kishimoto T. IL-6: from laboratory to bedside. Clin. Rev. Allergy Immunol. 2005, 28:177-186.
7. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
8. Chae H.D., Kim B.M., Yun U.J., Shin D.Y. Deregulation of Cdk2 causes bim-mediated apoptosis in p53-deficient tumors following actin damage. Oncogene 2008.
9. Ancrile B., Lim K.H., Counter C.M. Oncogenic ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007, 21:1714-1719.
10. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:9363-9367.
11. Ihle J.N. The stat family in cytokine signaling. Curr. Opin. Cell Biol. 2001, 13:211-217.
12. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
13. Kaptein A., Paillard V., Saunders M. Dominant negative stat3 mutant inhibits interleukin-6-induced Jak-STAT signal transduction. J. Biol. Chem. 1996, 271:5961-5964.
14. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
15. Jung M.S., Jin D.H., Chae H.D., Kang S., Kim S.C., Bang Y.J., Choi T.S., Choi K.S., Shin D.Y. Bcl-xL and E1B-19K proteins inhibit p53-induced irreversible growth arrest and senescence by preventing reactive oxygen species-dependent p38 activation. J. Biol. Chem. 2004, 279:17765-17771.
16. Shin D.Y., Sugrue M.M., Lee S.W., Aaronson S.A. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA 1997, 94:9648-9653.
17. Dumont P., Balbeur L., Remacle J., Toussaint O. Appearance of biomarkers of in vitro ageing after successive stimulation of WI-38 fibroblasts with IL-1alpha and TNF-alpha: senescence associated beta-galactosidase activity and morphotype transition. J. Anat. 2000, 197(Pt 4):529-537.
18. Goldstein S., Moerman E.J., Fujii S., Sobel B.E. Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome. J. Cell Physiol. 1994, 161:571-579.
19. Hodge D.R., Hurt E.M., Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer 2005, 41:2502-2512.
20. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., Travis W.D., Bornmann W., Veach D., Clarkson B., Bromberg J.F. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 2007, 117:3846-3856.
21. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., Ceccarelli C., Santini D., Paterini P., Marcu K.B., Chieco P., Bonafe M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
22. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., Matthews V., Schmid R.M., Kirchner T., Arkan M.C., Ernst M., Greten F.R. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
23. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
24. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
25. Hong D.S., Angelo L.S., Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007, 110:1911-1928.
26. Williams R.T., den Besten W., Sherr C.J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev. 2007, 21:2283-2287.
27. Mabb A.M., Miyamoto S. SUMO and NF-kappaB ties. Cell. Mol. Life Sci.: Cmls 2007, 64:1979-1996.
28. Mabb A.M., Wuerzberger-Davis S.M., Miyamoto S. PIASy mediates NEMO sumoylation and NF-kappaB activation in response to genotoxic stress. Nat. Cell Biol. 2006, 8:986-993.
29. Ducut Sigala J.L., Bottero V., Young D.B., Shevchenko A., Mercurio F., Verma I.M. Activation of transcription factor NF-kappaB requires ELKS, an IkappaB kinase regulatory subunit. Science 2004, 304:1963-1967.
30. Wu Z.H., Shi Y., Tibbetts R.S., Miyamoto S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 2006, 311:1141-1146.